The Role of Matrix Metalloproteinase 2 on the Survival of Patients with Non-Small Cell Lung Cancer: A Systematic Review with Meta-Analysis

被引：83

作者：

Qian, Qian ^{[1
]}

Wang, Qian ^{[1
]}

Zhan, Ping ^{[2
]}

Peng, Ling ^{[3
]}

Wei, Shu-Zhen ^{[1
]}

Shi, Yi ^{[1
]}

Song, Yong ^{[1
]}

机构：

[1] Nanjing Univ, Dept Resp Med, Jinling Hosp, Sch Med, Nanjing 210002, Peoples R China

[2] Nanjing Chest Hosp, Dept Resp Med, Nanjing 210029, Peoples R China

[3] Jinling Hosp, Dept Med Oncol, Nanjing 210002, Peoples R China

来源：

CANCER INVESTIGATION | 2010年 / 28卷 / 06期

关键词：

Matrix Metalloproteinase 2; NSCLC; Meta-analysis; Prognosis; PROGNOSTIC-FACTOR; PUBLICATION BIAS; EXPRESSION; MMP-2; ADENOCARCINOMA; INHIBITORS; CARCINOMA; OVEREXPRESSION; PROGRESSION; TRIALS;

D O I：

10.3109/07357901003735634

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

To evaluate the prognostic value of Matrix Metalloproteinase2 (MMP-2) expression in patients with non-small cell lung cancer (NSCLC), the electronic database PubMed, EMBASE were searched for relevant articles. The meta-analysis was finally based on 11 studies that included 1,439 patients, and combined HR was 1.66 (95% confidence intervals (Cl: 1.37-2.01). Its effect also appeared significant when the analysis was restricted to tumor cell expression and patients with adenocarcinoma (HR 2.08 (95% Cl: 1.24-3.48)). This study supported the fact that MMP-2 could be included in further prospective trials studying prognostic factors in NSCLC.

引用

页码：661 / 669

页数：9

共 50 条

[21] Clinical Outcomes of Alectinib for the Treatment of Non-Small Cell Lung Cancer Patients: A Systematic Review and Meta-Analysis
Luo, P.
Xia, Z.
Fan, J.
Liu, S.
Ye, J.
Xu, X.
Fong, T.
Zhang, J.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
[22] Hyponatremia as a prognostic factor in non-small cell lung cancer: a systematic review and meta-analysis
Sandfeld-Paulsen, Birgitte
Aggerholm-Pedersen, Ninna
Winther-Larsen, Anne
TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (02) : 651 - +
[23] Prognostic value of COX-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis
Zhan, Ping
Qian, Qian
Yu, Li-Ke
JOURNAL OF THORACIC DISEASE, 2013, 5 (01) : 40 - 47
[24] Anlotinib as treatment for advanced non-small cell lung cancer: A systematic review and meta-analysis on overall survival and progression free survival
Susanto, B.
Marcella, E.
Chen, S.
Heriyanto, R. S.
Tandiono, J.
Wijovi, F.
Tancherla, A.
Kurniawan, A.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S792 - S792
[25] The prognostic role of matrix metalloproteinase 2 in gastric cancer: a systematic review with meta-analysis
Weisong Shen
Hongqing Xi
Bo Wei
Lin Chen
Journal of Cancer Research and Clinical Oncology, 2014, 140 : 1003 - 1009
[26] The prognostic role of matrix metalloproteinase 2 in gastric cancer: a systematic review with meta-analysis
Shen, Weisong
Xi, Hongqing
Wei, Bo
Chen, Lin
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2014, 140 (06) : 1003 - 1009
[27] Predictive Role of Tumor-Stroma Ratio for Survival of Patients With Non-Small Cell Lung Cancer: A Meta-Analysis
Zhang, Xuefeng
Ma, Hongfu
Zhang, Liang
Li, Fenghuan
PATHOLOGY & ONCOLOGY RESEARCH, 2022, 27
[28] Matrix metalloproteinase polymorphisms and survival in stage I non-small cell lung cancer
Heist, Rebecca Suk
Marshall, Ariela L.
Liu, Geoffrey
Zhou, Wei
Su, Li
Neuberg, Donna
Lynch, Thomas J.
Wain, John
Christiani, David C.
CLINICAL CANCER RESEARCH, 2006, 12 (18) : 5448 - 5453
[29] The role of survivin on overall survival of non-small cell lung cancer, a meta-analysis of published literatures
Fan, Jiang
Wang, Lei
Jiang, Ge-Ning
He, Wen-Xin
Ding, Jia-An
LUNG CANCER, 2008, 61 (01) : 91 - 96
[30] Atezolizumab as first-line therapy for patients with advanced non-small cell lung cancer: A systematic review and meta-analysis on overall survival
Marcella, E.
Susanto, B.
Chen, S.
Tandiono, J.
Tancherla, A.
Heriyanto, R. S.
Wijovi, F.
Kurniawan, A.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S759 - S759

← 1 2 3 4 5 →